The pharma companies that will benefit most from AI over the next five years aren't only the ones with the best algorithms. They're the ones with the best data discipline.

The pharma companies that will benefit most from AI over the next five years aren't only the ones with the best algorithms. They're the ones with the best data discipline.

We see this firsthand every day.

A scientist at one of the biggest pharma companies was starting a new optimization campaign. Rather than beginning from scratch, they searched for related work from a colleague on a different team - someone who had run a similar campaign months earlier.

Everything was there. Structured, labeled, ready to use. A few clicks, and that historical campaign became a warm start for the new one. Institutional knowledge that would otherwise have stayed siloed in one team's folder was now actively accelerating work across the organization.

That's only possible when the data was captured correctly in the first place.

It starts with the basics - consistent metadata, lot numbers, timestamps, calibration records. Small habits that feel administrative in the moment but compound enormously over time.

But some of the most valuable information in chemistry lives in plain text - the order of addition, a note about phase separation, an unexpected observation. These details are easy to skip when you're moving fast. But they carry real scientific meaning.

This is exactly where Vera, @ReactWise's AI assistant, makes a genuine difference - reasoning across unstructured observations, spotting patterns across multiple campaigns, and surfacing insights that would otherwise remain invisible.

But Vera is only as powerful as the data it learns from. Clean, consistently captured data compounds. Inconsistent data doesn't.

Data discipline isn't glamorous. But in pharma R&D, it may be the highest-leverage investment you make this decade.

‍